| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Growth and Reproduction, Rigshospitalet, DK-2100 Copenhagen, Denmark
Address all correspondence and requests for reprints to: Anna-Maria Andersson, Department of Growth and Reproduction, Rigshospitalet, GR-5064, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. E-mail: anna{at}rh.dk.
| Abstract |
|---|
|
|
|---|
Seven boys with nonmosaic KS (karyotype 47,XXY) and 11 controls were followed with longitudinal serum inhibin B measurements every 312 months as they approached and entered puberty. None of the boys had significant bone age delay, and all entered puberty at the normal time and progressed through it at the expected time. In addition, 15 young adults with KS, aged 16.729.5 yr, were studied.
We found normal levels of inhibin B in prepubertal boys with KS and controls. In patients with KS as well as controls, inhibin B increased progressively before clinical pubertal onset. However, during late puberty inhibin B levels decreased gradually to the low/unmeasurable levels observed later in adult KS, while remaining unchanged in the controls.
| Introduction |
|---|
|
|
|---|
Even less is known about the Sertoli cell number and function in KS during childhood. The gonadal peptide hormone inhibin B is secreted by Sertoli cells in pre- and peripubertal boys, and the serum level of inhibin B is considered to reflect Sertoli cell function (8, 9). The onset of male puberty is associated with increasing serum concentration of inhibin B, and already by pubertal stage II the adult serum level of inhibin B has been reached (10). During puberty, as the Sertoli cells maturate, a change in the regulation of inhibin B production takes place, going from being solely Sertoli cell-dependent to being highly dependent on spermatogenesis (11). Thus, in adult men, the serum inhibin B level is a marker of spermatogenesis rather than a marker of Sertoli cell per se, and men with testicular dysfunction including adult patients with KS syndrome have very low or undetectable levels of inhibin B (9, 12, 13). To our knowledge, no studies exist of inhibin B during childhood and puberty in patients with KS. We report here a longitudinal inhibin B study on a group of patients with KS (karyotype 47,XXY) progressing through puberty and compare them to a group of age- and puberty-matched controls.
| Materials and Methods |
|---|
|
|
|---|
Eleven boys were followed longitudinally with clinical controls, including blood sampling for routine hormone measurements every 312 months as part of their clinical surveillance program, as they approached and entered puberty. For several years measurement of inhibin B levels has been part of the routine clinical care of patients with growth or reproduction problems attending our clinic, and thus longitudinal inhibin B levels were available. The median (range) age of the boys at the first measurement was 12.2 yr (10.313.1 yr), and the median (range) age for the last measurement was 14.2 yr (11.815.8 yr). None of the boys suffered from any genitourinary disorders, such as cryptorchidism or hypospadias. None had significant bone age delay; all entered puberty at the normal time and progressed through it at the expected time. One patient had isolated GH deficiency and received GH treatment. Four patients had skeletal dysplasias, and two of those received GH treatment. Four patients had familial short stature, and one of those received GH treatment. One patient had acquired hypothyreosis and received treatment with L-thyroxine. One patient had a pituitary incidentaloma and received no treatment. All of the boys, except the one with GH deficiency, had normal GH response to a challenge test. All of the boys, except the one with hypothyreosis, had normal basal thyroid function. All boys had a normal pituitary/gonadal function.
Longitudinal study of prepubertal boys with KS
Seven boys with KS (karyotype 47,XXY) were followed longitudinally with clinical controls and blood sampling for routine hormone measurements (including inhibin B) every 36 months as part of their clinical surveillance program as they approached and entered puberty. The median (range) age of the boys at the first measurement was 11.0 yr (8.912.6 yr), and the median (range) age for the last measurement was 13.7 yr (12.614.5 yr). In addition, longitudinal serum inhibin B levels were obtained from 15 young men with KS, aged 16.729.5 yr. In three patients, treatment with testosterone undecenoate (TU; 40 mg three times per week) was initiated before clinical onset of puberty. In one patient, treatment with TU was stopped approximately 2 yr after clinical onset of puberty and was followed by im injections of testosterone enanthate. The boys were otherwise healthy, without evidence of other endocrine or systemic disease.
Testicular size was determined using a Prader orchidometer. A testicular volume greater than 3 ml was taken as a definite sign of puberty. The onset of puberty was taken as the midpoint between the age of two adjacent dates with testicular volumes of 3 and 4 ml, respectively.
Cross-sectional inhibin B levels in normal 16- to 30-yr-old men used as reference material were obtained in two different projects approved by the local ethical committees and have been published in part previously (10, 14).
Hormone analyses
Samples were collected between midmorning and late afternoon. Inhibin B was determined by a double antibody enzyme immunometric assay (Oxford Bio-Innovation Ltd., Oxford, UK) using a monoclonal antibody raised against the inhibin ß-B subunit in combination with a labeled antibody raised against the
-subunit as previously described (15). The detection limit was 20 pg/ml, and intra- and interassay coefficients of variation were 15% and 18%, respectively. FSH and LH were measured by time-resolved immunofluorometric assay (DELFIA, Wallac, Inc. Turku, Finland) with detection limits of 0.06 and 0.05 U/liter, respectively. Intra- and interassay coefficients of variation were both less than 8% in the FSH and LH assays. Normal ranges for inhibin B, FSH, and LH levels in normal prepubertal boys have been published previously (10).
Statistics
If more than one blood sample from the same time period was available for the individual patients, the median value was calculated. Nonparametric statistics were used because data did not have a Gaussian distribution. Descriptive data were expressed as medians and ranges. Within-individual changes between successive time periods were tested by Wilcoxon signed-rank test. Any differences in inhibin B comparing same time periods between controls and KS was tested by the Mann-Whitney U test.
| Results |
|---|
|
|
|---|
|
Within-individual pair-wise comparisons between successive time periods indicated that inhibin B levels increased progressively before puberty: from 1224 month to 06 month (P = 0.03; n = 6). Inhibin B increased further during the 18-month period spanning the onset of puberty from 612 months before to 612 months after puberty onset (P < 0.05; n = 6), after which no further increase was found. Within-individual pair-wise comparisons between successive time periods indicated that FSH also increased progressively before puberty from 1.97 IU/liter (at 1224 months before pubertal onset) to 2.60 IU/liter (at 06 months before pubertal onset; P < 0.02; n = 7). FSH further increased during the 06 month period after the onset of puberty to 3.37 IU/liter (P < 0.05; n = 6), after which no further increase was found.
Klinefelter
Age at onset of puberty did not differ in controls and KS, with median ages of 12.9 (10.413.8) and 12.4 (11.613.7) yr, respectively. Within-individual pair-wise comparisons between successive time periods showed no significant differences in inhibin B before pubertal onset. After the onset of puberty, inhibin B decreased, but did not reach statistical significance (P = 0.11), probably due to the low number of data points. Before onset of puberty, no significant difference in inhibin B levels could be found between KS boys and the controls comparing same time periods. However, after the onset of puberty (from 06 months to 1224 months), inhibin B levels were significantly lower in boys with KS than in controls (P = 0.03).
Within-individual pair-wise comparisons between successive time periods indicated that FSH increased during the 12-month period spanning the onset of puberty from 1.23 to 1.33 IU/liter (P < 0.05; n = 6). Later in puberty, FSH seemed to increase further, but due to the low number of data points, this increase did not reach statistical significance. Comparing the same time periods before onset of puberty, no significant difference in FSH levels could be found between KS boys and the controls. After the onset of puberty, FSH levels tended to be higher in boys with KS compared with controls, although this difference was not statistically significant, possibly due to the low number of data points.
In the group of adolescent and young adult men with KS followed longitudinally [median (range), age of sampling, 20.6 (16.729.5) yr], only 3 of 15 patients had at a single occasion an inhibin B measurement just above the detection limit of the assay.
| Discussion |
|---|
|
|
|---|
In the control boys followed longitudinally, inhibin B increased progressively over the 2-yr period before onset of clinical puberty, with a further increase over the period spanning the onset of puberty. This is in agreement with the findings of Crofton et al. (21). No significant difference in FSH levels could be found between KS boys and the controls in prepuberty and early puberty. This is in line with the observation that significantly elevated levels of FSH only are observed in 16- to 18-yr-old KS several years after onset of puberty (3).
In controls and boys with KS, we defined a testicular volume greater than 3 ml as a definite sign of puberty and found no significant difference in age of onset of puberty between the two groups. This is in accordance with Ratcliffe et al. (22) who used the same definition of onset of puberty in KS. However, a testicular volume greater than 3 ml might not always indicate pubertal onset in KS, because serial measurements of prepubertal KS showed a reduced testicular size in several individuals (3). One might speculate that an increase in testicular volume from, e.g., 23 ml could indicate onset of puberty in some KS with a reduced prepubertal testicular volume. As a consequence, the age of onset of puberty in our boys with KS may in some cases have been overestimated, and this might explain the slightly higher prepubertal median level of inhibin B observed in our KS compared with the controls.
In several of our patients, the blood samples were collected during therapy with GH, L-thyroxine, or TU. Consideration must be given to whether this may have affected the results. However, it has been shown that therapy with either GH (21, 23) or L-thyroxine (23) has no significant effect on levels of inhibin B. Suppression of gonadotrophins with injections of testosterone (testosterone enanthate) was followed by a parallel decline in inhibin B levels in adult men (24). Little is known about the possible effect of TU on inhibin B levels. Brown et al. (25) in a double-blind, randomized trial found no significant effect of TU on basal or stimulated gonadotrophin levels during the 6-month treatment in boys with constitutional delay of growth. Similarly, a double-blind cross-over study in which men with hypo- and hypergonadotropic hypogonadism were treated with TU found no significant change in gonadotrophin concentration during treatment (26). Therefore, we do not expect that GH, L-thyroxine, or TU treatment significantly affected the observed inhibin B levels.
In conclusion, we found normal levels of inhibin B in prepubertal KS patients compared with a group of age- and puberty-matched controls, suggesting normal Sertoli cell function in prepubertal KS. During late puberty, inhibin B levels decreased gradually to the low/unmeasurable levels observed later in adult KS.
| Acknowledgments |
|---|
| Footnotes |
|---|
Abbreviations: KS, Klinefelter syndrome; TU, testosterone undecenoate.
Received August 30, 2002.
Accepted October 31, 2002.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
A. Balestrieri, L. Zirilli, B. Madeo, E. Pignatti, G. Rossi, C. Carani, and V. Rochira 21-Hydroxylase Deficiency and Klinefelter Syndrome in an Adult Man: Striking a Balance Between Androgen Excess and Insufficiency J Androl, November 1, 2008; 29(6): 605 - 609. [Full Text] [PDF] |
||||
![]() |
A. Juul, L. Aksglaede, A.M. Lund, M. Duno, N.E. Skakkebaek, and E. Rajpert-De Meyts Preserved fertility in a non-mosaic Klinefelter patient with a mutation in the fibroblast growth factor receptor 3 gene: Case Report Hum. Reprod., July 1, 2007; 22(7): 1907 - 1911. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Wikstrom, K. Bay, M. Hero, A.-M. Andersson, and L. Dunkel Serum Insulin-Like Factor 3 Levels during Puberty in Healthy Boys and Boys with Klinefelter Syndrome J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4705 - 4708. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Aksglaede, A. M. Wikstrom, E. R.-D. Meyts, L. Dunkel, N. E. Skakkebaek, and A. Juul Natural history of seminiferous tubule degeneration in Klinefelter syndrome Hum. Reprod. Update, January 1, 2006; 12(1): 39 - 48. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Wikstrom, T. Raivio, F. Hadziselimovic, S. Wikstrom, T. Tuuri, and L. Dunkel Klinefelter Syndrome in Adolescence: Onset of Puberty Is Associated with Accelerated Germ Cell Depletion J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2263 - 2270. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Lahlou, I. Fennoy, J.-C. Carel, and M. Roger Inhibin B and Anti-Mullerian Hormone, But Not Testosterone Levels, Are Normal in Infants with Nonmosaic Klinefelter Syndrome J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1864 - 1868. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |